SOLIGENIX, INC.

SNGXdata completeness 75%16 fiscal years on file
The thesis, from the filings

SOLIGENIX, INC. earns about -193% on equity, but has diluted owners by 94% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$824,2681$948,9112$839,3593$119,3714
Net income−$12.6M5−$13.8M6−$6.14M7−$8.27M8−$11.1M8
Operating cash flow−$11.7M9−$12.6M10−$8.6M11−$8.4M12−$10.3M12
Capital expenditure$5,88313
Free cash flow (derived)−$10.3M12
Total debt$014$1.01M15$015
Cash & equivalents$26M16$13.4M17$8.45M18$7.82M18$7.94M18
Diluted shares2.7M2.9M484,9951.7M5.2M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
$10.2
your share of equity
Profit it earned you last year
−$21.35
Free cash flow it threw off
−$19.8
Debt you’d be carrying

10 shares is a claim on $10.2 of net worth that earned you −$21.35 and generated −$19.8 of cash last year.

iii. Is this a good business?
Moat signal · return on equity
-193% avg · 5y
FY21 -117%FY22 FY23 -243%FY24 -201%FY25 -209%

It earned an average -193% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
+94% shares · 5y

Share count is up 94% over 5 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 1 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 1 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001558370-23-005304 (Revenues)
  2. 10-K · period ending 2022-12-31 · accession 0001558370-24-003402 (Revenues)
  3. 10-K · period ending 2023-12-31 · accession 0001558370-25-003459 (Revenues)
  4. 10-K · period ending 2024-12-31 · accession 0001104659-26-037701 (Revenues)
  5. 10-K · period ending 2021-12-31 · accession 0001558370-23-005304 (NetIncomeLoss)
  6. 10-K · period ending 2022-12-31 · accession 0001558370-24-003402 (NetIncomeLoss)
  7. 10-K · period ending 2023-12-31 · accession 0001558370-25-003459 (NetIncomeLoss)
  8. 10-K · period ending 2024-12-31 · accession 0001104659-26-037701 (NetIncomeLoss)
  9. 10-K · period ending 2021-12-31 · accession 0001558370-23-005304 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2022-12-31 · accession 0001558370-24-003402 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K · period ending 2023-12-31 · accession 0001558370-25-003459 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2024-12-31 · accession 0001104659-26-037701 (NetCashProvidedByUsedInOperatingActivities)
  13. 10-K · period ending 2025-12-31 · accession 0001104659-26-037701 (PaymentsToAcquirePropertyPlantAndEquipment)
  14. 10-K · period ending 2022-12-31 · accession 0001558370-24-003402 (LongTermDebt)
  15. 10-K · period ending 2023-12-31 · accession 0001558370-25-003459 (LongTermDebt)
  16. 10-K · period ending 2021-12-31 · accession 0001558370-22-004605 (CashAndCashEquivalentsAtCarryingValue)
  17. 10-K · period ending 2022-12-31 · accession 0001558370-25-003459 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
  18. 10-K · period ending 2023-12-31 · accession 0001104659-26-037701 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)